الفهرس 
Introduction and Aim of the workOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
AIM: Assessment of the neutralizing activity of human monoclonal antibodies against HCV and also study their safety in experimental
small animals (Swiss mice).
MATERIALS AND METHODS: Assessment of neutralizing activity of human monoclonal antibodies against HCV envelope regions (E1, E2) by two methods: by HCV cc infectious system for genotype, 2a (neutralization assay 1) and by using positive HCV positive serum as source of HCV particles, genotype 4a (neutralizing assay 2). Dot ELISA was used to study the activity of the generated antibodies. Safety and toxicity of the generated human antibodies were tested by assessing the changes in the biochemistry of liver function and kidney function tests, Complete blood counts (CBC) and study the pathological changes with different concentrations of purified human antibodies were carried out.
RESULTS: Human Abs # 5 & 11 showed neutralizing activity by (neutralizing assay 2) but were not neutralizing by HCV cc assay. Human Abs # 12 & 15 showed neutralizing activity by the two methods i.e our generated human antibodies Abs# 5 &11 & 12 & 15 were neutralizing for HCV genotype 4a and Abs # 12 & 15 were neutralizing for HCV genotypes 4a and 2a. Liver and kidney functions and CBC results indicated that doses of 10 _g, 100 _g were safe. The histopathological results indicated that the dose of 10 _g of purified human monoclonal antibodies per mouse body weight was safe.
CONCLUSION: The generated human monoclonal antibodies can be used to develop potent immunotherapy agents that can be administrated for the post-transplantation patients to prevent the recurrence of HCV infection. Also, the monoclonal antibodies can be used to in studies aim to develop a candidate vaccine against HCV.